TRAVERE THERAPEUTICS TVTX 深 沪
等待开盘 10-16 09:30:00 美东时间
26.71
+0.570
+2.18%
华盛通- 最 高27.00
- 今 开26.24
- 成交量 111.00万股
- 最 低 26.07
- 昨 收 26.14
- 总市值 23.81亿
- 52周最高 28.6927
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 12.91
- 委 比 12.20%
- 总股本 8913.87万
- 历史最高 37.04
- 量 比 0.80
- 振 幅 3.56%
- 历史最低 0.90
- 每 手 1
- 风险率 2.75%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Travere Therapeutics shares are trading higher. Guggenheim issued a Buy rating on the stock and a price target of $47.
Travere Therapeutics shares are trading higher. Guggenheim issued a Buy rating ...
10-07 01:02
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
09-30 01:35
KDIGO 2025 Guidelines Endorse FILSPARI By CSL Vifor And Travere Therapeutics Backed By PROTECT Trial Evidence For IgA Nephropathy
FILSPARI (sparsentan) suggested for IgA Nephropathy patients who are at risk of progressive kidney function loss
09-26 15:24
美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
09-15 11:13
美股大行评级 | 潜在涨幅208.48%！HC Wainwright & Co.上调Microbot Medical目标价至12美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Microbot Medical"买入"评级，目标价从9美元升至12美元；Maxim Group：维持Neuphoria Therapeutics"买入"评级，目标价从18美元升至35美元
09-12 12:53
美股牛股 | OpenAI超级大单催化！甲骨文狂飙超36%；VMEO升逾60%，达成重要收购协议
OpenAI超级大单催化！甲骨文狂飙超36%；VMEO升逾60%，达成重要收购协议；TVTX涨超26%，重要药物获FDA审评进展>>
09-11 15:32
Travere Shares Are Trading Higher Wednesday: What's Going On?
Travere Therapeutics, Inc. (NASDAQ:TVTX) shares are trading higher on Wednesday...
09-11 03:52
Daktronics, Potbelly, CoreWeave, GameStop And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Nasdaq Composite gaining around 100 points on ...
09-10 22:56
Travere Therapeutics Announces FDA Drops Advisory Committee For FILSPARI sNDA In FSGS; PDUFA Target Date Set For January 13, 2026
Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that following further review of the supplemental New Drug Application (sNDA) for
09-10 19:03
Travere Therapeutics (TVTX) Receives a Buy from H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Travere The...
09-03 22:55
